N-acetylcysteine in patients with COPD exacerbations associated with increased sputum;N-Acetylcystein bei Patienten mit Exazerbation einer COPD mit erhöhter Sputumproduktion

Wiener Klinische Wochenschrift

Volumn 127, Issue 7-8, 2015, Pages 256-261

  Ayfer Aytemur, Zeynep ^a   Baysak, Aysegul ^b   Ozdemir, Ozer ^c   Köse, Timur ^d   Sayiner, Abdullah ^d  

^a INONU UNIVERSITY   (Turkey)

^b IZMIR UNIVERSITY   (Turkey)

^c Siverek State Hospital   (Turkey)

^d EGE UNIVERSITY   (Turkey)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Mucolytic; N Acetylcysteine; Treatment

Indexed keywords

ACETYLCYSTEINE; EXPECTORANT AGENT;

AGED; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; HUMAN; MALE; PLACEBO EFFECT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL; SPUTUM; TREATMENT OUTCOME;

ACETYLCYSTEINE; AGED; DOUBLE-BLIND METHOD; EXPECTORANTS; FEMALE; HUMANS; MALE; PLACEBO EFFECT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM; TREATMENT OUTCOME;

EID: 84939996061     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-014-0692-4     Document Type: Article

References (16)

1. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648–54.
2. Kim V, Garfield JL, Grabianowski CL, Krahnke JS, Gaughan JP, Jacobs MR, Criner GJ. The effect of chronic sputum production on respiratory symptoms in severe COPD. COPD 2011;8:114–20.
3. Kasielski M, Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 2001;95:448–56.
4. Blesa S, Cortijo J, Mata M, Serrano A, Closa D, Santangelo F, Estrela JM, Suchankova J, Morcillo EJ. Oral N-acetylcysteine attenuates the rat pulmonary inflammatory response to antigen. Eur Respir J 2003;21:394–400.
5. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayk CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005;365:1552–60.
6. Black PN, Morgan-Day A, McMillan TE, Poole PJ, Young RP. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med. 2004;4:13.
7. American Thoracic Society: Standardized lung function testing: 1987 Update, Am Rev Respir Dis. 1987;136:1285–98
8. Quanjer PH, Tammeling GJ, Cotes JE, Pederson OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J Suppl. 1993;16:40.
9. Ram FSF, Poole PJ, Bagg W, Stewart J, Black PN. Randomised, controlled trial of theophylline for the treatment of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(suppl):A489
10. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153:1530–5
11. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J. 1995;8:1333–8
12. Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, Hersh CP, Stinson D, Silverman EK, Criner GJ, COPDGene Investigators. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011;140:626–33.
13. Sutherland ER, Crapo JD, Bowler RP. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD. 2006;3:195–202.
14. Decramer M, Janssens W. Mucoactive therapy in COPD. Eur Respir Rev. 2010;19:134–40.
15. Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomize placebo-controlled study. Lancet. 2008;371:2013–8
16. Zuin R, Palamidese A, Negrin R, Catozzo L, Scarda A, Balbinot M. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig. 2005;25:401–8.